Home

Senores Pharmaceuticals Ltd 52 Week High

Image

Senores Pharmaceuticals Ltd

NSE: SENORES

YEARHIGH

₹ 644.4

Last updated on: Mar 12, 2025

Key Highlights

  • The 52 Week HIGH of Senores Pharmaceuticals Ltd is ₹ 644.4 as of 12 Mar 25 .

Company Fundamentals for Senores Pharmaceuticals Ltd

Market Price of Senores Pharmaceuticals Ltd

1M

1Y

3Y

5Y

Monitoring Senores Pharmaceuticals Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
12 Mar 2025576.35
11 Mar 2025551.2
10 Mar 2025548.75
07 Mar 2025566.1
06 Mar 2025593.75
05 Mar 2025596.1
04 Mar 2025562.2
03 Mar 2025530.4
28 Feb 2025543.75
27 Feb 2025566.7

Asset Value vs Market Value of Senores Pharmaceuticals Ltd

Market Value

0

Asset Value

0

* All values are in ₹ crores

Historical Revenue of Senores Pharmaceuticals Ltd

No data available

* All values are in crore

Historical Net Profit of Senores Pharmaceuticals Ltd

No data available

* All values are in crore

Senores Pharmaceuticals Ltd News Hub

Senores Pharma spurts as PAT jumps to Rs 16 cr in Q3 FY25

Profit before tax stood at Rs 20.48 crore in the December 2024 quarter, up 99.61% from Rs 10.26 cror

Read more

23 Jan 25

Senores Pharma gets final approval for Metoprolol Tartrate and Hydrochlorothiazide tablets

Metoprolol Tartrate and Hydrochlorothiazide Tablet is the combination tablet of metoprolol tartrate,

Read more

10 Jan 25

Senores Pharmaceuticals IPO subscribed 93.41 times

The initial public offer (IPO) of Senores Pharmaceuticals received bids for 79,72,30,918 shares as a

Read more

24 Dec 24

Senores Pharmaceuticals receives USFDA approval for Metoprolol Tartrate and Hydrochlorothiazide Tablet

Senores Pharmaceuticals has received final approval from the United States Food and Drug Administrat

Read more

10 Jan 25

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

Data not available

FAQs for 52 Week High of Senores Pharmaceuticals Ltd

What is the significance of Senores Pharmaceuticals Ltd reaching its 52-week high?

Senores Pharmaceuticals Ltd reaching its 52-week high indicates strong market confidence and a positive outlook on the company's financial health and growth prospects. This milestone often reflects successful business performance and can boost investor sentiment.

Why do investors monitor Senores Pharmaceuticals Ltd 52-week high?

Investors monitor Senores Pharmaceuticals Ltd 52-week high to gauge the stock's peak performance and overall market strength, which can indicate robust financial health and growth potential. It also helps them assess if the stock is trading near its maximum value, influencing decisions on buying, holding, or selling.

Is Senores Pharmaceuticals Ltd a good buy when it hits its 52-week high?

Whether Senores Pharmaceuticals Ltd is a good buy at its 52-week high depends on various factors, including the company's future growth prospects, overall market conditions, individual investment strategies, and other important Senores Pharmaceuticals Ltd fundamentals.

What should I consider before investing in Senores Pharmaceuticals Ltd at its 52-week high?

Before investing in Senores Pharmaceuticals Ltd at its 52-week high, consider evaluating the company's recent financial performance, growth potential, and overall market conditions to ensure it aligns with your investment goals. Additionally, assess whether the stock's current valuation justifies the potential for future returns and if it fits your risk tolerance.

Can Senores Pharmaceuticals Ltd stock price continue to rise after reaching its 52-week high?

Senores Pharmaceuticals Ltd stock price can continue to rise after reaching its 52-week high if it maintains strong fiscal performance and favorable market conditions. However, future growth depends on numerous factors such as company earnings, industry trends, and broader economic conditions.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions